Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need

1

Inherited Orphan Blood Disorders Therapeutics
Market to 2019 - Breakthrough Drugs Remain
Elusive Against Backdrop of High Unmet Need

Published By GBI Research
Published January 2013
2
Description


GBI Research, the leading business intelligence
provider, has released its latest research,
Inherited Orphan Blood Disorders Therapeutics
Market to 2019 - Breakthrough Drugs Remain
Elusive Against Backdrop of High Unmet Need.
The report provides insights into the
up-and-coming trends of a portion of the
inherited orphan blood disorder pharmaceutical
market by examining sickle cell anemia,
thalassemia and Hereditary Angioedema (HAE) in
seven major markets the US, the top five
European countries (France, Germany, Italy, Spain
and the UK) and Japan. The report includes market
forecasts to 2019, detailed pipeline analysis,
in-depth profiling of major products and details
of recent industry deals. The sickle cell anemia
market will be the fastest growing of the three
markets during the forecast period with a
Compound Annual Growth Rate (CAGR) of 9 seeing
it reach 70m in 2019. The thalassemia market
will grow at a lower CAGR of 7 to reach 59m in
2019. HAE represents the largest but slowest
growing market, expected to reach 1.89 billion
by 2019 at a CAGR of 3.
3
Description


Scope - Current and future treatment trends for
three rare diseases - Market forecasts for three
rare diseases across seven major markets -
Analysis of the developmental pipelines for three
rare diseases - Information on recent industry
deals
4
Description

Reasons to buy - Understand how the inherited
orphan blood diseases market has developed and is
continuing to develop within the featured
markets - Predict which products are likely to be
most successful in the future - Gain an
understanding of the possible market available
for specific products
5
Table of Contents

• 1 Table of Contents
• 2 Inherited Orphan Blood Diseases - Introduction
• 3 Inherited Orphan Blood Disorders - Therapeutic
  Landscape
• 3.1 Sickle Cell Anemia
• 3.2 Sickle Cell Anemia Research and
  Development Pipeline
• 3.3 Thalassemia
• 3.5.1 Disease Overview
• 4 Inherited Orphan Blood Disorders Therapeutics -
  Strategic Consolidations
• 5 Inherited Orphan Blood Disorders Therapeutics -
  Appendix
• 5.1 Market Definitions
• 5.2 Abbreviations 76 5.3 Sources 76

6
Table of Contents

• 5.4 Research Methodology 775.4.1 Coverage
  775.4.2 Secondary Research 775.4.3 Primary
  Research 785.4.4 Therapeutic Landscape 785.4.5
  Geographical Landscape 
• For inquiry, kindly contact at
  http//www.reportsandintelligence.com/enquire-abou
  t-report/132360
• To check table of contents of the research, Visit
  _at_ http//www.reportsandintelligence.com/inherited
  -orphan-blood-disorders-therapeutics-to-2019-break
  through-drugs-remain-elusive-against-backdrop-of-h
  igh-unmet-need-market/table-of-contents

7

FOR MORE DETAILS
Visit us at
http//www.reportsandintelligence.com/inherited-or
phan-blood-disorders-therapeutics-to-2019-breakthr
ough-drugs-remain-elusive-against-backdrop-of-high
-unmet-need-reports-market
Stay With Us
TELEPHONE Direct 1 [phone] Toll Free
1 [phone]E-MAIL sales_at_reportsandintellig
ence.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States